Heron Therapeutics, Inc. $HRTX Position Boosted by Vanguard Group Inc.

Vanguard Group Inc. grew its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 0.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,225,585 shares of the biotechnology company’s stock after purchasing an additional 67,976 shares during the period. Vanguard Group Inc. owned approximately 5.39% of Heron Therapeutics worth $18,096,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Point72 Asset Management L.P. acquired a new position in shares of Heron Therapeutics in the fourth quarter worth about $4,706,000. AIGH Capital Management LLC acquired a new stake in shares of Heron Therapeutics during the first quarter worth approximately $6,112,000. Palisade Capital Management LP boosted its holdings in shares of Heron Therapeutics by 34.7% during the first quarter. Palisade Capital Management LP now owns 5,286,931 shares of the biotechnology company’s stock worth $11,631,000 after purchasing an additional 1,360,542 shares during the period. Stonepine Capital Management LLC acquired a new stake in shares of Heron Therapeutics during the fourth quarter worth approximately $1,071,000. Finally, New York State Common Retirement Fund boosted its holdings in shares of Heron Therapeutics by 32.7% during the first quarter. New York State Common Retirement Fund now owns 1,752,924 shares of the biotechnology company’s stock worth $3,856,000 after purchasing an additional 431,918 shares during the period. Institutional investors own 80.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on HRTX shares. Needham & Company LLC decreased their price target on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wall Street Zen cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Zacks Research raised shares of Heron Therapeutics to a “strong sell” rating in a research report on Tuesday, August 12th. Finally, HC Wainwright began coverage on shares of Heron Therapeutics in a research report on Monday, June 9th. They issued a “buy” rating and a $6.00 target price for the company. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.50.

Heron Therapeutics Trading Down 2.9%

Shares of Heron Therapeutics stock opened at $1.35 on Friday. The firm has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $1.97. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $2.68. The stock has a market capitalization of $206.94 million, a price-to-earnings ratio of -67.50 and a beta of 1.15.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Friday, August 8th. The biotechnology company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The firm had revenue of $37.20 million for the quarter, compared to analyst estimates of $38.08 million. Heron Therapeutics has set its FY 2025 guidance at EPS. As a group, research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Insiders Place Their Bets

In other Heron Therapeutics news, major shareholder Rubric Capital Management Lp acquired 2,387,225 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $1.50 per share, for a total transaction of $3,580,837.50. Following the purchase, the insider owned 29,100,728 shares in the company, valued at $43,651,092. This represents a 8.94% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Adam Morgan acquired 1,766,546 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $1.50 per share, for a total transaction of $2,649,819.00. Following the acquisition, the director owned 8,753,290 shares in the company, valued at approximately $13,129,935. The trade was a 25.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 5.86% of the company’s stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.